Moderna Stock Slides Again Friday: What's Going On?
Key takeaways
- Moderna’s stock fell despite encouraging trial results, reflecting investor uncertainty about the vaccine’s broader impact and valuation.
- MRNA shares down 4.04% to $194.45
- 17% drop on Thursday
- 42% reduction in recurrence or death risk
What happened
Moderna shares fell 4.04% to $194.45 in Friday pre‑market after a 17% drop on Thursday, driven by concerns over its personalized melanoma vaccine trial. The decline followed a leak of an abstract from the ESMO 2026 conference that raised questions about the vaccine’s effectiveness. Later that day, Moderna and Merck released full Phase 3 INTerpath‑001 results showing the combination of intismeran and Keytruda cut recurrence or death risk by 42% versus Keytruda alone, with stronger benefits…
Why it matters
The trial results confirm the vaccine’s clinical benefit, but the market reaction suggests investors are still wary of the data’s implications for valuation and broader tumor applications. The 42% reduction in recurrence or death risk is a significant therapeutic advance, yet the sell‑off indicates a disconnect…
Short-term and longer-term
Short-term. In the next few days, watch for any further commentary from Moderna or Merck on commercialization plans and pricing.
Longer-term. Over the coming months, the trial results could influence Moderna’s long‑term growth prospects, especially if the vaccine gains approval for multiple tumor types.